Picture loading failed.

Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-012-1mg 1mg 3090
GMP-Bios-ab-012-10mg 10mg 21890
GMP-Bios-ab-012-100mg 100mg 148000
GMP-Bios-ab-012-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Afasevikumab biosimilar, Whole mAb, Anti-IL17A/IL17 Antibody: Anti-CTLA-8/CTLA8A/ILA17 therapeutic antibody
INN Name Afasevikumab
TargetIL17
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI Structure6ppg:HL:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesNovImmune;Genentech
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAutoimmune disorders;Inflammation
Development Techna